Insights Into Diffuse Large B-Cell Lymphoma (DLBCL)

Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape

Florida – February 9, 2024

Faculty Chair

Nikesh Shah, MD

Tampa General Hospital, Tampa, FL, USA

Southwest – February 24, 2024

Faculty Chair

John Burke, MD

Rocky Mountain Cancer Centers, Aurora, CO, USA

Southeast – March 15, 2024

Faculty Chair

Amitkumar Mehta, MD

University of Alabama, Birmingham, AL, USA

Central – April 20, 2024

Faculty Chair

Mazyar Shadman, MD

Fred Hutchinson Cancer Center, Seattle, WA, USA

Northeast – August 24, 2024

Faculty Chair

Shazia K. Nakhoda, MD

Fox Chase Cancer Center, Philadelphia, PA, USA

Midwest – September 21, 2024

Faculty Chair

Nirav Shah, MD

Stanford University School of Medicine, Stanford, CA, USA

Boston – October 26, 2024

Faculty Chair

Matthew Lunning, DO, FACP

University of Nebraska Medical Center, Omaha, NE, USA

More Information

  • Tampa, FL
  • Florida

More Information

  • Scottsdale, AZ
  • Arizona, Colorado, Nevada, New Mexico, Southern California, Utah

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Dallas, TX
  • Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas 

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

MORE INFORMATION

  • Chicago, IL
  • Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin

MORE INFORMATION

  • Boston, MA
  • Massachusetts, New York, New Hampshire

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of DLBCL
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, and polatuzumab vedotin

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.